These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29272720)

  • 21. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
    Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
    J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
    Loo AS; Muhsin SA; Walsh TJ
    Expert Opin Drug Saf; 2013 Nov; 12(6):881-95. PubMed ID: 23931455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion.
    Dórea EL; Yu L; De Castro I; Campos SB; Ori M; Vaccari EM; Lacaz Cda S; Seguro AC
    J Am Soc Nephrol; 1997 Sep; 8(9):1415-22. PubMed ID: 9294833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.
    Kang JY; Gao J; Shin DH; Alvarez C; Zhong W; Kwon GS
    Pharm Nanotechnol; 2016; 4(1):16-23. PubMed ID: 27774409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S; Imai S; Yabuki M; Komuro S
    Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
    Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
    Saliba F; Dupont B
    Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels.
    Arning M; Kliche KO; Heer-Sonderhoff AH; Wehmeier A
    Mycoses; 1995; 38(11-12):459-65. PubMed ID: 8720196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.
    Egito ES; Araújo IB; Damasceno BP; Price JC
    J Pharm Sci; 2002 Nov; 91(11):2354-66. PubMed ID: 12379920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.
    Joly V; Farinotti R; Saint-Julien L; Chéron M; Carbon C; Yeni P
    Antimicrob Agents Chemother; 1994 Feb; 38(2):177-83. PubMed ID: 8192439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.
    Hossain MA; Maesaki S; Razzaque MS; Tomono K; Taguchi T; Kohno S
    J Antimicrob Chemother; 2000 Aug; 46(2):263-8. PubMed ID: 10933650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate---fat emulsion in HIV-infected patients with oral candidosis.
    Chavanet P; Clement C; Duong M; Buisson M; D'Athis P; Dumas M; Bonnin A; Portier H
    Clin Microbiol Infect; 1997 Aug; 3(4):455-461. PubMed ID: 11864156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.